Inside the design loop: A day in the life of a digital medicinal chemist
Date & Time 
Location - Virtual
There is often a gap between knowing a tool exists and knowing how to actually use it to drive a program forward. In this session, we’re stepping away from the high-level overviews to give you an honest look at how medicinal chemists at Schrödinger actually work.
We’ll take you behind the scenes for a “day in the life” walkthrough with a member of our Schrödinger Therapeutics Group (STG). You’ll see exactly how we use LiveDesign as our centralized hub to move past static data and into real-time collaboration with all members of the project team.
What we’ll dive into:
-
The Design Hub: How we centralize team data in LiveDesign to stop “searching” for results and start making cohesive decisions
-
Applied Workflows: A transparent look at how we deploy WaterMap, Ligand Designer, and predictive modeling for CNS permeability and hERG inhibition to prioritize the right analogs
-
From Prediction to Synthesis: How retrosynthesis tools and real-time integration help us focus on the molecules that actually move the needle
Who should attend:
-
Medicinal Chemists looking to replace fragmented spreadsheets with a real-time, integrated design space
-
Bench Scientists interested in how computational tools could fit into their daily workflow
-
Synthetic Chemists who want a practical look at using retrosynthesis to efficiently prioritize synthesis
-
Discovery Program Leads who need to synchronize chemistry and modeling teams to hit milestones faster
Our Speakers
Daigo Inoyama
Senior Principal Scientist, Medicinal Chemistry, Schrödinger Therapeutics Group, Schrödinger
Daigo Inoyama is a Senior Principal Scientist at Schrödinger who joined the company in 2018. As a medicinal chemist in the Schrödinger Therapeutics Group (STG), he coordinates interdisciplinary drug discovery teams working across multiple disease areas. He holds a PhD in Medicinal Chemistry from Rutgers University with expertise in integrating rational drug design with computational approaches to accelerate discovery of novel therapeutics. Prior to joining Schrödinger, his postdoctoral work with Professor Joel Freundlich in infectious diseases including tuberculosis, contributed to the development of a promising compound targeting M. tuberculosis KasA.
David Papin
Principal Scientist II, Schrödinger
David Papin joined Schrödinger in 2024 as an Application Scientist. David has a background in chemistry and computational chemistry. He held positions in computational sciences in the industry, providing in silico support for small and large molecule projects.
Steven Jerome
Executive Director, Life Science Software, Schrödinger
Dr. Steven Jerome completed his PhD at Columbia University in the Chemistry Department under the supervision of Richard Friesner. While at Columbia, he contributed to tools for molecular docking and protein structure refinement. After Columbia, he joined Schrödinger as a scientific developer working on the Glide team, before transitioning to product management. He has since advanced through several roles at Schrödinger to his current dual role as Executive Director of Hit Discovery, directing the development of a broad portfolio of state-of-the-art computational tools for small molecule hit identification and head of EU+ Application Science, supporting greater adoption of the Schrödinger platform within Europe.